Kornimate/medical-research-clean huggingface dataset:
study of value of dexamethasone used in ovulation induction

Conditions: Infertility, Female

Summary: this study intends to solve the following problems: whether use dexamethasone can obviously decrease transplant cancelling probability in fresh embryo transplant cycle or not, reduce time and frequency going to hospital repeatedly for patients need frozen embryo transplant or not, and reduce the economic burden for patients or not; by comparing pregnancy rate of single transplant, hope to make clear in ivf-et treatment for patients progesterone increases to a certain level whether it is a good choice to transfer fresh embryo after dexamethasone treatment, or frozen embryo transplant is better.


Eligibility criteria:
inclusion criteria: - female, 18 years old≤age≤35 years old, 18≤bmi≤25, standard patient, menstrual regularity exclusion criteria: hyperprolactinemia, thyroid dysfunction, uterine malformation ( inadequacy mediastinal uterus ≥1.0cm, unicornate uterus, double uterus, t angle of uterus, etc.), uterus adhesion, untreated hydrosalpinx , hysteromyoma（ hysteromyoma≥1.0 cm, and/or endometrial hysteromyoma≤1 cm), endometriosis, diabetes, hypertension, adrenal cortex hyperplasia, cushing's syndrome, a pituitary amenorrhea
use of atorvastatin (lipitor) to decrease panel reactive antibody titers

Conditions: End-Stage Kidney Disease

Summary: the purpose of this study is to identify subjects who are highly sensitized with antibodies. it is difficult for these patients to find suitable kidneys. we propose to treat such patients to decrease the antibodies in such a way, that it may become possible to safely transplant kidneys into them.

kidney transplantation is the desired treatment of choice in subjects with end-stage kidney disease (esrd). the average waiting time for subjects to receive a "deceased donor" kidney transplant is 3-5 years. currently, there are about 60,000 subjects on the national waiting list, and about 13,000-14,000 kidney transplants are performed each year. approximately, 25% of subjects on the waiting list are "highly sensitized", meaning that they have natural proteins (antibodies) that aggressively protect their bodies from the invasion of foreign proteins. these individuals often have a difficult time accepting transplanted kidneys. the purpose of this study is to identify subjects who are highly sensitized with these antibodies, and treat them in such a way, that it may become possible to transplant kidneys into them. drugs like atorvastatin (lipitor) may decrease the levels of these anti-bodies and increase the possibility of these subjects to receive a kidney transplant. this research study is being done because currently, there are very limited and cumbersome treatment options to address this issue, subjects who are highly sensitized with antibodies, may unfortunately wait for a very long time or may never get transplanted.

Eligibility criteria:
inclusion criteria: 1. eighteen years or older, 2. on the waiting list for a kidney transplant list 3. on hemodialysis or peritoneal dialysis exclusion criteria: 1. pregnant woman 2. patients who need ongoing blood products 3. patients with failed organs having active rejection 4. other therapies to decrease pra 5. patients listed for multi-organ transplants (other than kidney-pancreas)

Keywords: kidney disease, lipitor, atorvastatin, allosensitization
efficacy of high-precision transcranial direct current stimulation on anxiety disorders

Conditions: Anxiety Disorders; High-definition Transcranial Direct Current Stimulation

Summary: 1. current research has found that tdcs has a positive effect on improving the negative attention bias of ad patients, and this study uses hd-tdcs intervention to improve the cognitive function and neural mechanisms of ad patients in the ofc to provide a theoretical basis for ad neural mechanism research. verify hypothesis 1: hd-tdcs cathodal stimulation of the left ofc reduces the excitability of this region, modulates its connectivity with the attentional function network, and thus changes the emotional experience of social threat. 2. currently, there is no consensus on the stimulation parameters for tdcs in the treatment of ad, and more evidence is needed to prove and explore. it is hoped that the hd-tdcs intervention protocol will become an effective treatment method for improving cognitive function and clinical symptoms in ad patients. hypothesis 2: the hd-tdcs with intensified stimulation parameters (2ma, twice a day, with a 20-minute interval, for 5 consecutive days) has an impact on the main and secondary clinical variables of ad patients.


Eligibility criteria:
inclusion criteria: 1. meet the dsm-5 ad diagnostic criteria; 2. the chinese version of the brief international neuropsychiatric interview (mini) screening meets the diagnosis; 3. age: 18-55 years old; 4. the patient participated voluntarily, obtained the consent of the family members, and signed the informed consent form; 5. scale score criteria: 14 points on the hamilton anxiety scale (hama) and 17 points on the hamilton depression scale (hamd). exclusion criteria: 1. neurological diseases or other psychiatric disorders; 2. severe somatic diseases; 3. received medical treatment including medication, psychotherapy, electroconvulsive therapy, and physical therapy within the first half months of enrollment; 4. tdcs examination contraindications, such as intracranial metal or electronic implants, skull plate, or other skull implants. 5. pregnancy and lactation.
selection criteria for safe hepatectomy for hepatocellular carcinoma

Conditions: Hepatectomy; Hepatecellular Carcinoma; Cirrhosis

Summary: selection criteria for safe hepatectomy for hcc are not well established. the aim of this study was the validation of the selection criteria for safe hepatectomy for hepatocellular carcinoma.

all consecutive patients submitted to hepatectomy for hcc based on the same preoperative selection criteria from our prospectively-maintained liver unit database. such criteria included the value of bilirubin (bil), the value of cholinesterases (che), the presence of ascites, the presence of esophageal varices, and the rate of residual liver volume.

Eligibility criteria:
inclusion criteria: * any patient with hcc submitted to hepatic resection at our unit in the established frame time exclusion criteria: * any patient with missing data or lost at follow-up
primary testicular lymphoma

Conditions: Testicular Lymphoma

Summary: 742 / 5.000 a 57-year-old male: denies chronic degenerative, allergic, traumatic, transfusional, or surgical complications. he denies a family history of testicular cancer or abnormalities in testicular descent. the patient presented with an enlarged right testicle that had been present for 1 month. he saw his family doctor, who prescribed antibiotic and analgesic treatment, without improvement, and was referred to our service. upon examination, the right testicle was palpable, nontender, slightly enlarged, indurated, with nodulations measuring 0.5 cm in diameter, and free spermatozoa. the left testicle was normal. he underwent radical orchiectomy, which revealed renal testicular lymphoma.

a 57-year-old male: denies chronic degenerative, allergic, traumatic, transfusional, or surgical complications. he denies a family history of testicular cancer or abnormalities in testicular descent. the patient presented with an enlarged right testicle that had been present for 1 month. he saw his family doctor, who prescribed antibiotic and analgesic treatment, without improvement, and was referred to our service. upon examination, the right testicle was palpable, non-tender, slightly enlarged, indurated, with nodulations measuring 0.5 cm in diameter, and free spermatozoa. the left testicle was normal. he underwent radical orchiectomy, which revealed renal-testicular lymphoma. on the first postoperative day, the patient began to have stools with malignant cells and discontinuous invasion of the umbilical cord. he was evaluated by the gastroenterology department, who indicated the performance of an endoscopy, which revealed a 6 cm bleeding gastric ulcer. a biopsy was taken and a diffuse b-cell lymphoma was detected. he was evaluated by the gastroenterology department, who indicated the performance of an endoscopy, which revealed a large lesion. on the first postoperative day, the patient began to have stools with malignant cells and discontinuous invasion of the umbilical cord. he was evaluated by the gastroenterology department, who indicated the performance of an endoscopy, which revealed a large lesion. the patient continued to have melena and grade iv anemia. he was referred to pathology, where he was found to have oms. he showed no improvement despite blood transfusions. he died. immunohistochemistry for both testicular lesions and on the third postoperative day.

Eligibility criteria:
inclusion criteria: * patient with testicular lymphoma exclusion criteria: * patient without testicular lymphoma

Keywords: testis lymphoma nodal stomach
laboratory profile of hepatitis b and c in users of a reference service

Conditions: Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted; Hepatitis B, Chronic

Summary: chronic hepatitis by the b virus (hbv) and/or by the c virus (hcv) is a major public-health problem since it presents a long phase of clinical latency which makes its early diagnosis difficult and results in the development of a large number of cases to complications such as cirrhosis, hepatic insufficiency and hepatocarcinoma. in brazil, it is estimated that the number of hbv is two million, of which 72 thousand have been reported. as regards hcv, the ratio is one of three million estimated cases to 52 thousand reports. learning about the serological profile of the users of a viral hepatitis reference service is fundamental for the planning of diagnostic and caregiving actions; therefore, it is the objective of this study.

chronic hepatitis by virus b (hvb) and/or by virus c (hvc) is a major public-health problem since it presents a long phase of clinical latency which makes its early diagnosis difficult and results in the development of a large number of cases to complications such as cirrhosis, hepatic insufficiency and hepatocarcinoma. in brazil, it is estimated that the number of hvb patients is two million, but only 72 thousand have been reported. as regards hvc, the ratio is three million estimated cases to 52 thousand reports. learning about the serological profile of the users of a viral hepatitis reference service is essential for the planning of diagnostic and therapeutic actions; therefore, it is the objective of this study. five hundred and thirty-one hvb and hvc serological profiles of the patients referred to sae/hd within a period of 18 months (january 2006 to june 2007) were studied by means of retrospective analysis. the patients were classified as: a) hbv: carrier, cure, isolated anti-hbc and vaccinated; b) hvc: reagent anti-hvc; c) hbv/hvc co-infection: aghbs and reagent anti-hvc; and d) susceptible: non-reagent serology. as regards hbv, the following were found from the total number of patients: carriers, 12.6%; cure, 18.9%; isolated anti-hbc, 9.0% and vaccinated, 6.2%. the patients with reagent anti-hvc comprised 31.3% of the total number of individuals. hbv/hcv co-infection was 0.6%. susceptible individuals comprised 20.5%. it was concluded that approximately 45% of the referred patients carried chronic infection by b and/or c virus, a condition which requires additional investigation and, in many instances, specific treatment. strategies for early diagnosis are essential in order to prevent the intrinsic complications of such condition.

Eligibility criteria:
inclusion criteria: * patients with laboratory tests positive for hepatitis b and/or c exclusion criteria: * no laboratory tests available
study to evaluate safety, tolerability, pharmacokinetics and the food effect on pk of asc10 tablets in healthy subjects

Conditions: SARS CoV 2 Infection

Summary: this is a phase i, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of asc10 tablets and an open-label, crossover design to evaluate the food effect on pk of asc10 in healthy subjects


Eligibility criteria:
inclusion criteria: * male or female volunteers between the ages 18 and 45, inclusive * those who do not have plans for pregnancy within six months and are willing to take effective contraceptive measures from the first dose of the study drug to 3 months after the last dose. * if male, agree to use adequate contraception throughout the study and for at least 3 months after the last dose of study drug. * body mass index (bmi) was between 19 and 26 kg/m\^2. weight ≥50 kg for males and ≥45 kg for females. exclusion criteria: * females who are pregnant, planning to become pregnant, or breastfeeding. * has any current or historical disease or disorder of the hematological system or significant liver disease or family history of bleeding/platelet disorders. * has a history of cancer (other than basal cell or squamous cell cancer of the skin), rheumatologic disease or blood dyscrasias. * has a history of blood dizziness or difficulty in blood collection. * has donated blood within 30 days, plasma within 2 weeks, or platelets within 6 weeks before the first dose of study drug.

Keywords: asc10 rdrp healthy
study of tauroursodeoxycholic acid for hepatobiliary disease in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: objectives: i. determine the optimum dose of tauroursodeoxycholic acid (tudca) required to achieve maximal bioavailability for patients with cystic fibrosis-associated liver disease. ii. compare optimized doses of tudca with ursodiol (ursodeoxycholic acid; udca) for effects on biliary bile acid composition and metabolism, serum biochemistries, fat absorption, and fat-soluble vitamin status in these patients.

protocol outline: objective i: this part of the study is a dose-response study to determine the optimal dose of tauroursodeoxycholic acid (tudca). twenty-four patients are randomized to receive one of three different doses of tudca for 3 months. objective ii: this part of the study is a double-blind crossover study to compare optimized doses of tudca with optimized doses of ursodiol in 15 patients stratified according to age (less than 10 vs 10-20 vs more than 20 years). patients are randomized to receive either tudca or ursodiol orally for an initial 3 month period, followed by a 3 month washout period in which no drug is administered. patients then receive the alternate drug for 3 months. completion date provided represents the completion date of the grant per oopd records

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * cystic fibrosis-associated liver disease, defined by at least one of the following criteria: (1) documented increase in serum concentrations of any of the liver enzymes (at least once in the preceding year) alt at least twice normal ast at least 1.5 times normal alkaline phosphatase at least 1.5 times normal ggt at least 1.5 times normal (2) persistent hepatomegaly of more than 6 months duration defined by percussed liver span greater than 1 sem for age (3) splenomegaly, defined as a palpable spleen greater than 2.0 cm below the left costal margin (4) abnormalities of ultrasound scan (increased size, dishomogeneous echogenicity, nodular liver, irregular margins, splenomegaly) within 6 months prior to study entry * patients enrolled in the first part of the study (objective i) are eligible to participate in the second part (objective ii) --prior/concurrent therapy-- * at least 3 months since prior ursodiol * at least 3 months since treatment with drug with choleretic properties or effects that influence bile acid metabolism --patient characteristics-- * hepatic: no decompensated cirrhosis no hepatic neoplasm or cholelithiasis * pulmonary: no significantly impaired pulmonary function with fev1 less than 50% * other: at least 15 kg body weight no severely compromised clinical or nutritional state

Keywords: cardiovascular and respiratory diseases cystic fibrosis genetic diseases and dysmorphic syndromes rare disease
3-d reconstruction of ct scan images in the evaluation of non-specific pulmonary nodules

Conditions: Undiagnosed Pulmonary Nodules; Lung Nodules

Summary: in recent years, more and more people are having lung ct scans performed to screen for various cancers. many of them have small abnormalities detected, called "nodules", which - for a variety of reasons - doctors are unable to biopsy. as a result, many patients have their ct scans repeated on a regular basis to see if their nodules grow. this process can last several years. many patients experience significant anxiety during this process, when they are aware of a spot in the lung, but are not told any specific cause. researchers at memorial sloan-kettering have developed a new way to look at lung nodules in three dimensions. the purpose of this project is to see if any change in the nodules can be detected sooner by this method than by traditional ct scans.


Eligibility criteria:
inclusion criteria: * referral to the pulmonary or thoracic surgery service for undiagnosed pulmonary nodules. * history of smoking exceeding 10 pack-years (pack year defined as number of packs of cigarettes per day multiplied by the number of years smoked). * age \>18 * nodule size 5 to 15 mm in diameter. exclusion criteria: * clinical indication for immediate biopsy via bronchoscopy, fine needle aspiration, or video-assisted thoracoscopic surgery (vats) * active lung cancer or metastasis to the lung. * contraindication to needle biopsy. * pneumonectomy * need for supplemental oxygen. * radiation pneumonitis * interstitial lung disease.
plexus brachialis block. better to do by start than by end of surgery?

Conditions: Pain

Summary: the aim of the study is to find out if the timing of brachial plexus block, before or after surgery, has an impact of the extent of acute postoperative surgical pain or the incidence and severity of long-lasting (chronic) pain after surgery. this is a prospective, randomized, double blind study in patients with radial fractures undergoing surgery with volar plate. the patients will be followed up for 6 months after surgery.


Eligibility criteria:
inclusion criteria: * radial fracture * asa 1 and 2 * able to communicate in norwegian * suitable for surgery in general anaesthesia and brachial plexus block exclusion criteria: * pregnancy * chronic pain * bmi over 35

Keywords: pain
live feedback to increase adherence in adolescents with patellofemoral pain

Conditions: Patellofemoral Pain Syndrome; Musculoskeletal Disorders; Joint Diseases

Summary: this study investigates if live feedback during home-based exercises will improve the ability to perform the exercises with the prescribed time under tension (tut) per repetition compared with no feedback among adolescents with patellofemoral pain. the hypothesis is that adolescents who receive live feedback from bandcizer™ will have a mean tut that is significantly closer to the prescribed tut compared to the group not receiving feedback during the course of the intervention.


Eligibility criteria:
inclusion criteria: * 15 to 19 years of age * anterior knee pain of non-traumatic origin which is provoked by at least two of the following activities: prolonged sitting with bended knees or kneeling, squatting, running, jumping or ascending or descending stairs * tenderness on palpation of the peripatellar borders * pain of more than 6 weeks duration * worst pain during the previous week ≥ 30 mm on a 100 mm vas exclusion criteria: * concomitant pain from other structures in the knee (e.g. ligament, tendon or cartilage), the hip or the lumbar spine * previous knee surgery * patellofemoral instability

Keywords: adolescent physical therapy modalities exercise intervention auditive feedback visual feedback
specific inspiratory muscle training (simt)in the patients with ventilatory dependence

Conditions: Ventilatory Defect

Summary: prolong mechanical ventilation cause to respiratory muscle weakness and high risk to weaning failure,the investigators hypothesize that 1. specific inspiratory muscle training (simt) using threshold loaded breathing device (breathemax v.1)in patients with ventilator dependence will improve inspiratory muscle strength 2. simt will improve lung function in patients with ventilatory dependence. 3. simt will improve weaning success in patients with ventilatory dependence.

prolonged mechanical ventilation cause detrimental effects on lung function and high risk of lung complications and standard weaning protocols are not successful in a number of patients. the strength of the inspiratory muscles is important factors in the success of weaning. although, the inspiratory muscles are trained by manipulating the ventilator sensitivity and made of ventilation in the traditional protocol, the muscle function might not improved sufficiently to sustain independent and spontaneous breathing. consequently, specific inspiratory muscle training is indicated and has been studied in patient with weaning failure. however, there is little evidence available and no firm conclusion can be drown. therefore, the purpose of this study is to determine whether specific imt training using the local made loaded threshold imt device can improve lung function and accelerate the weaning process.

Eligibility criteria:
inclusion criteria: * patient who have been mechanically ventilated \> 72 hours and start to weaning from medical order or ventilator dependent patients who have failed to wean prior to study. * normal arterial blood gas (paco2 \ 60 mmhg on fio2 \ 90%, ph 7.35-7.45). * cardiovascular stability (hr ≤ 140 beats/min, systolic bp 90-140 mmhg and diastolic bp 60-90 mmhg, with no or minimal vasopressors) * good consciousness, cooperation and can sit in an upright position \> 30 minutes exclusion criteria: * persistent homodynamic instability. * severe breathlessness at rest when spontaneous breathing. * coronary heart disease with angina. * life threatening arrhythmia (vf, vt). * sedation ramsay scale \> 2 * severity of disease apache ii score \> 29

Keywords: specific inspiratory muscle training(simt) loaded deep breathing weaning mechanical ventilation respiratory muscle